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Association Between Abnormal 
REM Sleep and Negative 
Symptoms in Schizophrenia 
To the Editors: 
Although shortened rapid eye movement 
(REM) sleep latency, increased REM den- 
sity, and decreased slow-wave sleep (SWS) 
are considered characteristic features of en- 
dogenous depression (Kupfer et al., 1978), 
several studies have reported similar findings 
in schizophrenic patients (reviewed in Zar- 
cone et al., 1987). The latter observed that on 
the basis of REM abnormality, medication-free 
schizophrenic patients were indistinguishable 
from patients with major depression. The pre- 
cise implications of these sleep findings in 
schizophrenia are unclear. The present study 
was conducted to evaluate the frequency and 
nature of abnormalities in the sleep electroen- 
cephalogram (EEG) in a group of medication- 
free schizophrenic patients and to investigate 
the association of such abnormalities with 
positive, negative, and depressive symptoms 
in schizophrenia. 
Methods 
The sample consisted of IO consecutively 
hospitalized inpatients who met DSM-III- R 
(American Psychiatric Association, 1987) 
criteria and Research Diagnostic Criteria 
(Spitzer et al., 1978) for schizophrenia (five 
male and five female; mean age = 28. I years; 
mean duration of illness = 6.9 years). All 
patients had been medication free for at least 
2 weeks. EEG sleep was monitored for 2 con- 
secutive nights, with data from the second 
night being used for analysis. In addition to 
standard sleep variables, a discriminant func- 
tion (DF) score (Feinberg et al., 1982) was 
calculated. DF scores represent a linear 
combination of REM density and REM laten- 
cy, with DF scores < I.0 indicating signifi- 
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cant REM abnormality and being consistent 
with the sleep of endogenous depressives; 
normal controls and nonendogenous patients 
have DF scores > I .O. Patients were rated on 
the Brief Psychiatric Rating Scale (BPRS) 
(Overall and Gorham, 1962) Scale for the 
Assessment of Negative Symptoms (SANS) 
(Andreasen, 1983) and the l7-item Hamilton 
Rating Scale for Depression (HRSD) (Ham- 
ilton, 1960). Comparisons of demographics 
and rating scale scores between patients with 
and without REM abnormalities (DF scores 
< I .O and > I .O, respectively) were made by 
the two-tailed Student’s t test. Pearson pro- 
duct-moment correlation analysis between 
symptom ratings on the one hand and 
measures of REM abnormality (DF score) 
and SWS (Time of Stage 4 Sleep) on the 
other were also conducted. 
Results 
Four of the IO patients showed significant 
REM abnormalities with DF scores < 1.0. 
Patients with and without REM abnormali- 
ties did not differ in age, sex distribution, 
total duration of illness, or duration of cur- 
rent psychotic exacerbation. The two groups 
also did not differ in global severity, positive 
symptoms, or depressive symptoms. The two 
groups differed significantly in negative symp- 
toms: patients with REM abnormalities (DF 
score < I .O) had significantly greater negative 
symptoms (t = 6.99, df = 8, p < 0.001). 
Patients with REM abnormalities (DF scores 
< 1.0) were also noted to have significantly 
less SWS and Stage 4 non-REM sleep specifi- 
cally, in conformity with the usually observed 
association between these sleep findings. 
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Pearson correlations between the various 
clinical and sleep variables revealed no signifi- 
cant association between positive symptoms, 
depressive symptoms, and global severity on 
the one hand and any of the sleep variables 
on the other. There was a significant negative 
correlation between the baseline DF score 
and negative symptoms (Fig. I). A similar nega- 
tive correlation was noted between minutes 
of Stage 4 non-REM sleep and negative symp- 
toms (r = -0.64, df = 8, p < 0.05). 
Fig. 1. Correlational analysis between 
baseline negative symptoms and discrim- 
inant function score (REM abnormality) 
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While these findings are clearly of a prelimi- 
nary nature, they suggest that a significant 
number of schizophrenic patients may have 
reduced REM latency and decreased SWS- 
findings that have often been considered to 
typify sleep in endogenous depression. Fur- 
thermore, these sleep findings did not appear 
to be related to depressive symptoms in schiz- 
ophrenia, but were significantly correlated 
with the severity of negative symptoms. This 
association of decreased REM latency and 
increased REM density with negative symp- 
toms in schizophrenic patients suggests that 
the sleep findings and negative symptoms 
may have similar underlying mechanisms. 
Cholinergic mechanisms are important in 
sleep regulation, particularly with regard to 
the onset or timing of the first REM period 
(Sitaram et al., 1977). Based on the similarity 
in the behavioral profile produced by cholin- 
ergic overdrive and the negative schizophrenic 
syndrome (Greden et al., 1987) response of 
negative symptoms to anticholinergic treat- 
ment (Tandon et al., 1988), neuroendocrine 
and other data (Tandon and &eden, 1988, in 
press), cholinergic hyperactivity has also 
been proposed as a possible mechanism in 
the production of negative schizophrenic 
symptoms. While alternative mechanisms 
need to be considered, the association 
between REM abnormalities and negative 
symptoms observed in our study is consistent 
with the implication of increased muscarinic 
activity in the pathophysiology of both 
negative symptoms and altered REM sleep in 
patients suffering from schizophrenia. 
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